#USA #Boston #Huntington's Disease #Skyhawk Therapeutics #SKY-0515

Skyhawk Therapeutics Reports Promising Results for SKY-0515 in Huntington's Disease

On September 16, 2026, Skyhawk Therapeutics, a biotechnology company focused on RNA-targeted therapies, announced encouraging outcomes from their Phase 1/2 clinical trial involving SKY-0515, an oral investigational treatment for Huntington's Disease (HD). This study marks a significant step forward in addressing a disease that currently lacks approved therapies capable of modifying its course.

Trial Overview

The trial was designed as a randomized, double-blind, placebo-controlled study assessing two dosage levels (4 mg and 9 mg) of SKY-0515 over twelve weeks, followed by a twelve-month extension period where all participants received the active treatment. Notably, 200 patients were recruited across twenty clinical sites in ten countries, underscoring the international effort to effectively combat this debilitating disorder.

Key Findings

At the culmination of fifteen months, patients receiving SKY-0515 exhibited a substantial mean improvement of 0.94 points on the composite Unified Huntington's Disease Rating Scale (cUHDRS) compared to a control group, which experienced a deterioration of 0.65 points. The mean difference of 1.59 points was statistically significant (p < 0.001), showcasing the potential efficacy of SKY-0515.

In examining the components of cUHDRS, patients receiving the treatment showed improvements in total functional capacity (+0.98 points), motor scores (-9.38 points), processing speed (+4.15 points), and reading speed (+4.18 points), all statistically relevant measures that indicate SKY-0515's impact on daily functioning, motor skills, and cognitive abilities.

The consistent reduction of over 60% in mutant huntingtin protein (mHTT) and a 25% decrease in PMS1 mRNA with the 9 mg dosage further reinforces the compound's mechanism of action, addressing critical pathways implicated in the progression of Huntington’s disease.

Tolerability and Safety

Throughout the fifteen-month period, SKY-0515 demonstrated a strong safety profile, with no severe adverse events reported that were linked to the treatment. This is particularly important for patients with Huntington's Disease, who often face numerous health challenges due to the progressive nature of the disorder.

Dr. Samuel Frank, a leading expert at the Huntington's Disease Society of America, highlighted the significance of these results, stating, “The 1.59-point difference on the cUHDRS scale is the kind of result we hope to see from potential therapeutic agents.” He emphasized that the consistent improvements across functional, motor, and cognitive measures call for further exploration in placebo-controlled studies.

Community Response

Katie Jackson, CEO of Help 4 HD International, expressed her optimism regarding the results, noting the societal impact of having a once-daily oral treatment available, which could substantially enhance the lives of Huntington's patients, especially those in rural areas with limited access to healthcare.

Personal testimonies underline the urgency of new treatments: “I hope that my children and thousands of families like mine will receive timely treatment in the future,” a patient advocate remarked, emphasizing the transformative potential of this therapy.

Future Directions

Skyhawk Therapeutics is poised to advance the development of SKY-0515 following the promising Phase 1/2 results. The company is also progressing toward their pivotal Phase 2/3 clinical trial, FALCON-HD, aiming to expand the understanding of SKY-0515's impact on Huntington’s disease among larger patient populations.

As researchers and advocates eagerly anticipate further data from the ongoing trials, the hope for a viable treatment option for Huntington's Disease becomes more palpable. With no currently approved therapies that can slow disease progression, the results from SKY-0515 offer a beacon of hope for patients and families affected by this challenging condition.

For more information about SKY-0515 and ongoing trials, please visit Skyhawk Therapeutics.